Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 04, 2025 08:00 ET | Source: Mestag Therapeutics Ltd.

Mestag Therapeutics Appoints Dr. Matthew Sleeman as Chief Scientific Officer

CAMBRIDGE, United Kingdom, March 04, 2025 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease...
December 09, 2024 08:00 ET | Source: Mestag Therapeutics Ltd.

Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform

CAMBRIDGE, United Kingdom, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, today announced that...
November 13, 2024 08:00 ET | Source: Mestag Therapeutics Ltd.

Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General Counsel

CAMBRIDGE, United Kingdom, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, today announced that it...
October 08, 2024 07:00 ET | Source: Mestag Therapeutics Ltd.

Mestag Therapeutics Announces License and Research Collaboration with MSD to Identify Novel Targets for Inflammatory Diseases

CAMBRIDGE, United Kingdom, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, today announced that it...
August 28, 2024 08:24 ET | Source: Mestag Therapeutics Ltd.

Mestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300

- Innovate UK, part of UK Research and Innovation, is investing £10 million in innovation projects to advance next-generation immunotherapies for cancer, of which £1.5 million has been awarded to...
April 08, 2024 12:00 ET | Source: Mestag Therapeutics Ltd.

Mestag Presents Preclinical Data at AACR on its M300 Program, a Conditionally Active LTBR Agonist Designed to Induce Tertiary Lymphoid Structures in Tumors

CAMBRIDGE, United Kingdom, April 08, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions, is today presenting data...
March 05, 2024 16:30 ET | Source: Mestag Therapeutics Ltd.

Mestag Therapeutics’ M300 Program, Designed to Conditionally Induce Tertiary Lymphoid Structures in Tumors, Selected for Late-Breaking Poster Presentation at AACR Annual Meeting

CAMBRIDGE, United Kingdom, March 05, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions to develop impactful...
February 28, 2024 08:00 ET | Source: Mestag Therapeutics Ltd.

Mestag Therapeutics to Present at Evercore ISI 2024 Emerging Biotech Conference

CAMBRIDGE, United Kingdom, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions to develop impactful...
February 20, 2024 08:00 ET | Source: Mestag Therapeutics Ltd.

Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its Lead Oncology Program

CAMBRIDGE, United Kingdom, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Mestag Therapeutics (“Mestag”), a biotech company harnessing new insights into fibroblast-immune interactions to develop impactful...